Figure 3.

EGT improves CTL functionality in tumor in combination with TLR2/6 ligand. (A–C) LLC-OVA-implanted WT B6 mice were treated as per Figure 1A and tumors were harvested at day 18. (A) Concentration of IFN-γ and TNF-α in tumor was determined by cytometric beads assay (CBA). Data were pooled from two independent experiments resulted in similar profiles. n = 4–10 mice per group. (B) Total tumor cells were re-stimulated with 50 nM of SL8 peptide for 6 h. Brefeldin A was supplied during last 5 h of culture. Then, intracellular expression levels of IFN-γ and TNF-α in CD8⁺ CD3⁺ cells were detected by flowcytometry. Representative data are shown as FACS plot. n = 4–5 mice per group. (C) Cell surface expression of indicated proteins on CD8⁺ CD3⁺ cells were analyzed by flowcytometry. n = 4–5 mice per group. *P < 0.05, **P < 0.01. n.s., not significant.